What is Zacks Research’s Forecast for CORT Q1 Earnings?

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Zacks Research reduced their Q1 2026 EPS estimates for Corcept Therapeutics in a research report issued to clients and investors on Wednesday, January 14th. Zacks Research analyst Team now anticipates that the biotechnology company will earn ($0.31) per share for the quarter, down from their previous estimate of $0.04. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2026 earnings at ($0.06) EPS and FY2026 earnings at $0.43 EPS.

CORT has been the topic of several other research reports. Wall Street Zen lowered Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, October 18th. UBS Group initiated coverage on shares of Corcept Therapeutics in a research report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price objective on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Canaccord Genuity Group cut their target price on shares of Corcept Therapeutics from $140.00 to $99.00 and set a “buy” rating for the company in a research report on Friday, January 2nd. Finally, Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a report on Wednesday, December 31st. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Corcept Therapeutics presently has an average rating of “Hold” and an average price target of $80.83.

Corcept Therapeutics Stock Performance

NASDAQ CORT opened at $34.73 on Monday. The business has a 50 day moving average price of $69.09 and a 200 day moving average price of $72.25. The company has a market capitalization of $3.65 billion, a P/E ratio of 39.47 and a beta of 0.23. Corcept Therapeutics has a 1-year low of $32.99 and a 1-year high of $117.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.14 and a quick ratio of 3.07.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). The company had revenue of $207.64 million for the quarter, compared to analyst estimates of $223.78 million. Corcept Therapeutics had a net margin of 14.19% and a return on equity of 15.99%. Corcept Therapeutics’s revenue was up 13.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.41 earnings per share.

Institutional Investors Weigh In On Corcept Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CORT. Advisory Services Network LLC acquired a new stake in Corcept Therapeutics in the 3rd quarter worth about $25,000. Clearstead Advisors LLC lifted its holdings in shares of Corcept Therapeutics by 163.6% during the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 193 shares during the period. Golden State Wealth Management LLC acquired a new stake in shares of Corcept Therapeutics in the second quarter worth approximately $28,000. Huntington National Bank boosted its position in shares of Corcept Therapeutics by 54.0% in the second quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 168 shares during the last quarter. Finally, Hantz Financial Services Inc. grew its holdings in Corcept Therapeutics by 598.5% in the third quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 395 shares during the period. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Insider Activity

In related news, insider Sean Maduck sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $79.52, for a total transaction of $1,590,400.00. Following the transaction, the insider owned 7,904 shares of the company’s stock, valued at approximately $628,526.08. This represents a 71.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider William Guyer sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $35.18, for a total transaction of $703,600.00. Following the sale, the insider owned 1,235 shares in the company, valued at approximately $43,447.30. This trade represents a 94.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 194,500 shares of company stock worth $14,186,410. Corporate insiders own 20.80% of the company’s stock.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks Research raised its Q4 2027 EPS estimate for CORT to $1.29 from $1.12, a small upside to that specific quarter despite the firm’s overall bearish stance. Read More.
• Positive Sentiment: Zacks also nudged up its Q4 2026 EPS estimate to $0.49 from $0.43 — another isolated upward revision that could be seen as modestly supportive for near-term quarterly expectations. Read More.
• Neutral Sentiment: Coverage pieces are highlighting Corcept’s profit profile versus peers and discussing growth prospects; these help keep the company on investors’ radar but don’t change fundamentals by themselves. Read More.
• Neutral Sentiment: Industry comparisons (e.g., profitability vs. a faster-growing rival) provide context for valuation debates but are not immediate catalysts. Read More.
• Negative Sentiment: Zacks Research downgraded CORT from “hold” to a “strong sell” and trimmed several near-term and FY2027 EPS forecasts (multiple cuts to Q1–Q3 2026/2027 and a FY2027 cut to $3.21 from $3.35). The downgrade and lower multi-quarter estimates are a clear negative catalyst for sentiment and can pressure the stock. Read More.
• Negative Sentiment: Multiple law firms (Pomerantz, Schall, DJS) have announced investigations alleging potential misstatements or nondisclosures; the emergence of shareholder litigation risk typically weighs on investor sentiment and can create legal and reputational uncertainty. Read More. Read More. Read More.
• Negative Sentiment: An outside price-target cut was reported (a ~28% reduction to $92.82), which can recalibrate upside expectations and contribute to selling pressure from valuation-conscious investors. Read More.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.